A Phase IV, Randomised, Controlled, Single Masked Study Investigating the Efficacy and Safety of Ranibizumab "Inject and Extend" Using an Intensive Retinal Fluid Retreatment Regimen Compared to a Relaxed Retinal Fluid Retreatment Regimen in Patients With Wet Age-related Macular Degeneration (AMD)

Trial Profile

A Phase IV, Randomised, Controlled, Single Masked Study Investigating the Efficacy and Safety of Ranibizumab "Inject and Extend" Using an Intensive Retinal Fluid Retreatment Regimen Compared to a Relaxed Retinal Fluid Retreatment Regimen in Patients With Wet Age-related Macular Degeneration (AMD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms FLUID
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 22 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 28 Feb 2017 Planned End Date changed from 1 Nov 2016 to 30 Mar 2017.
    • 28 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 30 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top